Highbridge Capital Management’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Highbridge Capital Management’s Portfolio NVLN Stock Details NVLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-215,000	Closed	-$1.81M	–	1847
2016 Q4	$1.81M	Buy	+215,000	New	+$1.9M	0.03%	400

Other funds holding NVLN

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

FSA

Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return

Highbridge Capital Management's NVLN Position: Q4 2019 in Review

Highbridge Capital Management sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q4 2019, closing a stake of 581,042 shares — an estimated $421K sold.

Highbridge Capital Management first reported a position in NVLN in Q1 2017 and held it in 7 quarters. The position peaked at $10.7M in Q2 2017. 7 funds tracked by Wall St. Rank hold NVLN as of Q4 2019.

Highbridge Capital Management reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q4 2019 after selling out during the quarter.
Highbridge Capital Management sold 581,042 Novelion Therapeutics Inc. Common Shares shares in Q4 2019, an estimated $421K.
Highbridge Capital Management first reported a position in Novelion Therapeutics Inc. Common Shares in Q1 2017 and held it in 7 quarters.
Highbridge Capital Management's Novelion Therapeutics Inc. Common Shares position peaked at $10.7M in Q2 2017.
7 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q4 2019.

Based on Highbridge Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.